Quantitative proteomic analysis of down syndrome biomarkers in maternal serum using isobaric tags for relative and absolute quantification (iTRAQ)

Abstract

Prenatal diagnosis of Down syndrome (DS) is based on calculated risk involving maternal age, biochemical and ultrasonographic markers, and, more recently, cell-free DNA (cfDNA). The present study was designed to identify Down Syndrome biomarkers in maternal serum. We quantified the changes in maternal serum protein levels between 10 non-pregnant women, 10 pregnant women with healthy fetuses, and 10 pregnant women with DS fetuses using isobaric tags for relative and absolute quantification (iTRAQ). We subsequently conducted a Gene Ontology (GO) analysis. A total of 470 proteins were identified, 11 of which had significantly different serum levels between the DS fetus group and Healthy fetuses group. Our data shows the identified proteins may be relevant to DS and constitute potential DS biomarkers.

摘要

唐氏综合症（DS）的产前诊断基于计算的风险, 包括母亲年龄, 生化和超声标记, 以及最近的游离DNA（cfDNA）。本研究旨在确定产妇血清中的唐氏综合征生物标志物。我们使用等压标记（isobaric tags for relative and absolute quantification, iTRAQ）对10名非孕妇、10名健康胎儿孕妇和10名DS胎儿孕妇的血清蛋白水平变化进行了量化。我们随后进行了GO（Gene Ontology）分析, 共鉴定出470个蛋白, 其中11个蛋白在DS胎儿组和健康胎儿组血清中有显著性差异。我们的数据显示, 识别出的蛋白质可能与DS相关, 并构成潜在的DS生物标志物。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Keywords:

• Prenatal diagnosis
• aneuploidy
• proteomics
• trisomy 21

Disclosure statement

No potential conflict of interest was reported by the authors.